Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action

British Journal of Haematology

Volumn 189, Issue 5, 2020, Pages 846-847

  Kollias, Anastasios ^a   Kyriakoulis, Konstantinos G ^a   Dimakakos, Evangelos ^a   Poulakou, Garyphallia ^a   Stergiou, George S ^a   Syrigos, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

anticoagulant; prophylaxis; SARS CoV 2; thromboembolism; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; HYPERTENSIVE FACTOR; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

AGING; ANTICOAGULANT THERAPY; CEREBROVASCULAR ACCIDENT; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG SAFETY; HEART FAILURE; HEMATOLOGY; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; IMMOBILIZATION; INCIDENCE; INTENSIVE CARE UNIT; MALIGNANT NEOPLASM; MEDICAL HISTORY; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MORTALITY RATE; MORTALITY RISK; NOTE; OBESITY; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; RISK FACTOR; SEDATION; SEPSIS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; BETACORONAVIRUS; BLOOD; CORONAVIRUS INFECTION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; MALE; METABOLISM; PANDEMIC; VIROLOGY; VIRUS PNEUMONIA;

ANTICOAGULANTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INCIDENCE; MALE; PANDEMICS; PNEUMONIA, VIRAL; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 85083993663     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.16727     Document Type: Note

References (10)

1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7.
2. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehaa254.
3. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14830.
4. Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, Lugosi M, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care. 2015;19:287.
5. Malato A, Dentali F, Siragusa S, Fabbiano F, Kagoma Y, Boddi M, et al. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus. 2015;13:559–68.
6. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14817.
7. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2007575.
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
9. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. published: 25 March 25, 2020. https://clotconnect.wpcomstaging.com/2020/03/26/covid-19-and-coagulopathy-two-management-guidance-documents-for-health-care-professionals/. https://doi.org/10.1111/jth.14810
10. COVID-19 and VTE/Anticoagulation: Frequently asked questions. https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation